Formulary Decisions

Search for the outcome of decisions made by the Formulary Committee

Filter
Select filter(s)
Bimekizumab
Bimzelx
Routinely available
SMC (SMC2410)
25/11/2025

Indication

Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. SMC restriction: for patients who have failed to respond to standard systemic therapies (including ciclosporin, methotrexate and phototherapy), are intolerant to, or have a contra-indication to these ...

Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. SMC restriction: for patients who have failed to respond to standard systemic therapies (including ciclosporin, methotrexate and phototherapy), are intolerant to, or have a contra-indication to these treatments.

Therapeutic Area

Skin

Status Description

Routinely available in line with national guidance

Formulation

solution for injection in pre-filled syringe and pre-filled pen

Comments

.

Link to Advice

SMC2410

Advice Published

08/11/2021

SMC Submission Type

Abbreviated

SMC Status

Restricted